

FITC anti-mouse CD3 Antibody

Catalog# / Size	100203 / 50 µg 100204 / 500 µg
Clone	17A2
Regulatory Status	RUO
Other Names	T cell antigen receptor complex, T3
Isotype	Rat IgG2b, κ
Description	CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	γδTCR-positive T-T hybridoma D1
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm)
Application Notes	Additional reported application (for relevant formats) include: spatial biology (IBEX) ^{1,2} .
Application References (PubMed link indicates BioLegend citation)	<ol style="list-style-type: none">1. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) PubMed2. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) PubMed
Product Citations	<ol style="list-style-type: none">1. Harsha Krovi S, <i>et al.</i> 2020. <i>Nat Commun.</i> 4.790277778. PubMed2. Dai L, <i>et al.</i> 2020. <i>Cell.</i> 182(3):722-733.e11. PubMed3. Xing J, <i>et al.</i> 2021. <i>Cell Reports.</i> 35(12):109205. PubMed4. Zaman R, <i>et al.</i> 2021. <i>Immunity.</i> PubMed5. Yu X, <i>et al.</i> 2020. <i>Nat Commun.</i> 11:1110. PubMed6. Jiang W, <i>et al.</i> 2017. <i>Sci Rep.</i> 7:6501. PubMed7. Petrova T, <i>et al.</i> 2020. <i>Sci Rep.</i> 10:3479. PubMed8. Zhang H, <i>et al.</i> 2021. <i>Front Immunol.</i> 12:644520. PubMed9. Garo LP, <i>et al.</i> 2021. <i>Nat Commun.</i> 12:2419. PubMed10. Lee JH, <i>et al.</i> 2022. <i>EBioMedicine.</i> 77:103903. PubMed11. Zhu Y, <i>et al.</i> 2022. <i>Nat Commun.</i> 13:4282. PubMed12. Bruggemann TR, <i>et al.</i> 2022. <i>iScience.</i> 25:105185. PubMed

13. Miller CM, *et al.* 2020. J Virol. 94:00:00. [PubMed](#)
14. Boyd DF, *et al.* 2020. Nature. 587:466. [PubMed](#)
15. Wu X, *et al.* 2012. Biochem Pharmacol. 84:1164. [PubMed](#)
16. Lin W, *et al.* 2020. Theranostics. 10:4871. [PubMed](#)
17. Gawish R, *et al.* 2022. Elife. 11:.. [PubMed](#)
18. Qiao Y, *et al.* 2021. Oncoimmunology. 10:1947569. [PubMed](#)
19. Li Q, *et al.* 2022. Cell Rep. 40:111308. [PubMed](#)
20. Manukian G, *et al.* 2021. Int J Radiat Oncol Biol Phys. 110:1341. [PubMed](#)
21. Jiang Q, *et al.* 2022. Theranostics. 12:59. [PubMed](#)
22. Wilhelm J, *et al.* 2021. J Control Release. 329:353. [PubMed](#)
23. Ford K, *et al.* 2020. Cancer Res. 80:1846. [PubMed](#)
24. Delvecchio FR, *et al.* 2021. Cell Mol Gastroenterol Hepatol. 12:1543. [PubMed](#)
25. Zhang R, *et al.* 2021. Cell Mol Immunol. 18:1222. [PubMed](#)
26. Tang L, *et al.* 2021. Oncol Lett. 22:605. [PubMed](#)
27. Kim D, *et al.* 2021. Nanomicro Lett. 13:31. [PubMed](#)
28. Bao H, *et al.* 2020. Mol Med Rep. 4:675. [PubMed](#)
29. Du Q, *et al.* 2019. Front Microbiol. 10:2050. [PubMed](#)
30. Song C, *et al.* 2019. Nat Commun. 10:3745. [PubMed](#)
31. Liu QZ, *et al.* 2018. Front Immunol. 1.131944444. [PubMed](#)
32. Chou YJ, *et al.* 2020. Sci Rep. 10:8422. [PubMed](#)
33. Bromley SK, *et al.* 2020. Cell Reports. 32(9):108085. [PubMed](#)
34. Turner JA, *et al.* 2020. Immunity. 53:1202. [PubMed](#)
35. Jiang W, *et al.* 2021. Oncol Lett. 22:625. [PubMed](#)
36. Choi YY, *et al.* 2021. Cell Death Dis. 12:826. [PubMed](#)
37. Almeida AS, *et al.* 2021. Bio Protoc. 11:e4012. [PubMed](#)
38. Zhang S, *et al.* 2022. Acta Pharm Sin B. 12:3124. [PubMed](#)
39. Steubing RD, *et al.* 2022. Brain Behav Immun Health. 24:100493. [PubMed](#)
40. Mei S, *et al.* 2022. Front Immunol. 13:911164. [PubMed](#)
41. Lu H, *et al.* 2021. Autophagy. 17:2511. [PubMed](#)
42. Fu Y, *et al.* 2020. Mol Ther. 1214:28. [PubMed](#)
43. Sun CC, *et al.* 2020. Genome Med. 0.553472222. [PubMed](#)
44. Schmidleithner L *et al.* 2019. Immunity. 50(5):1232-1248 . [PubMed](#)
45. Diao L, *et al.* 2022. iScience. 25:105511. [PubMed](#)
46. Bangs DJ, *et al.* 2022. Cell Rep. 38:110266. [PubMed](#)
47. Huang Y, *et al.* 2021. Radiother Oncol. 162:34. [PubMed](#)
48. Zhao J, *et al.* 2022. J Nanobiotechnology. 20:62. [PubMed](#)
49. Ren J, *et al.* 2021. Theranostics. 11:304. [PubMed](#)
50. Tan X, *et al.* 2021. Front Oncol. 11:768222. [PubMed](#)
51. Oliva Chávez AS, *et al.* 2021. Nat Commun. 12:3696. [PubMed](#)
52. Liu Q, *et al.* 2021. Cell Death Dis. 12:240. [PubMed](#)
53. Starkl P, *et al.* 2020. Immunity. 53(4):793-804.e9. [PubMed](#)
54. Antonia O Cuff *et al.* 2017. Wellcome open research. 2:39 . [PubMed](#)
55. Davis FM, *et al.* 2019. Arterioscler Thromb Vasc Biol. 39:2353. [PubMed](#)
56. Pham THM, *et al.* 2020. Cell Host & Microbe. 27(1):54-67.e5.. [PubMed](#)
57. Lesmeister M, *et al.* 2005. Reprod Biol Endocrinol. 29:74. [PubMed](#)
58. Dolgova EV, *et al.* 2022. Int J Mol Sci. 23:.. [PubMed](#)
59. Mostafavi H, *et al.* 2022. PLoS Pathog. 18:e1010185. [PubMed](#)
60. Sala D, *et al.* 2022. Mol Ther Methods Clin Dev. 25:170. [PubMed](#)
61. Yu AI, *et al.* 2020. Cell Rep. 107471:31. [PubMed](#)
62. Jiang S, *et al.* 2020. Scand J Immunol. e12867:91. [PubMed](#)
63. Perner C, *et al.* 2020. Immunity. 53(5):1063-1077.e7. [PubMed](#)
64. White C, *et al.* 2014. J Immunol. 193:5933. [PubMed](#)
65. Chen Y, *et al.* 2012. PLoS One. 7:e47190. [PubMed](#)
66. Ning X, *et al.* 2019. Mol Cell. 74:19. [PubMed](#)
67. Uchimura T *et al.* 2018. Immunity. 49(6):1049-1061 . [PubMed](#)
68. Deng P, *et al.* 2022. Cells. 11:.. [PubMed](#)
69. Li Y, *et al.* 2022. Clin Transl Immunology. 11:e1362. [PubMed](#)
70. Zhan Y, *et al.* 2021. JCI Insight. 6:.. [PubMed](#)
71. Lee M, *et al.* 2014. PLoS One. 9:112666. [PubMed](#)
72. Mingozzi F, *et al.* 2016. EMBO Mol Med. 8: 1039 - 1051. [PubMed](#)
73. Solanki A, *et al.* 2018. Development. 145. [PubMed](#)
74. Shields BD, *et al.* 2019. Cancer Res. 79:1113. [PubMed](#)
75. Dang Y, *et al.* 2022. Cancer Cell Int. 22:88. [PubMed](#)
76. Almeida AS, *et al.* 2021. Bio Protoc. 11:e4012. [PubMed](#)
77. Geng T, *et al.* 2022. Methods Mol Biol. 2585:71. [PubMed](#)
78. Park HB, *et al.* 2020. Oncoimmunology. 9:1772663. [PubMed](#)
79. Kimball AS *et al.* 2019. Immunity. 51(2):258-271 . [PubMed](#)
80. Naing A *et al.* 2019. Cell reports. 26(5):1242-1257 . [PubMed](#)
81. Yang S, *et al.* 2019. Nat Commun. 10:2782. [PubMed](#)
82. Carr RM, *et al.* 2021. Nat Commun. 12:2901. [PubMed](#)
83. Pervaiz N, *et al.* 2021. Pigment Cell Melanoma Res. 34:918. [PubMed](#)
84. Sun Y, *et al.* 2022. Nat Commun. 13:3916. [PubMed](#)
85. Zhang B, *et al.* 2021. Nat Biomed Eng. 5:1288. [PubMed](#)
86. Chen Q, *et al.* 2016. Nat Commun. 7:13193. [PubMed](#)
87. Bogie JF, *et al.* 2020. Ther Adv Chronic Dis. 11:2040622320947378. [PubMed](#)
88. Li Y, *et al.* 2020. Cell Stem Cell. 27(5):732-747.e7. [PubMed](#)
89. Omori S, *et al.* 2021. Cell Reports. 34(6):108734. [PubMed](#)
90. Wang X, *et al.* 2018. Mol Med Rep. 17:1660. [PubMed](#)
91. Lee JS *et al.* 2018. Cell. 174(6):1559-1570 . [PubMed](#)
92. Comazzetto S *et al.* 2018. Cell stem cell. 24(3):477-486 . [PubMed](#)

93. Littwitz-Salomon E, *et al.* 2021. *Nat Commun.* 12:5376. [PubMed](#)
94. Hanasoge Somasundara AV, *et al.* 2021. *Cell Rep.* 37:110099. [PubMed](#)
95. Shi R, *et al.* 2022. *Theranostics.* 12:875. [PubMed](#)
96. Jie X, *et al.* 2022. *J Immunother Cancer.* 10: [PubMed](#)
97. Harb H, *et al.* 2021. *Immunity.* 54(6):1186-1199.e7. [PubMed](#)
98. Tacconi C, *et al.* 2021. *Cell Reports.* 35(2):108993. [PubMed](#)
99. Elahi S, *et al.* 2020. *Stem Cell Res.* 43:101710. [PubMed](#)
100. Akhter N, *et al.* 2016. *J Biol Chem.* 291: 23672 - 23680. [PubMed](#)
101. Huang B, *et al.* 2015. *PLoS One.* 10: 0134715. [PubMed](#)
102. Markey K, *et al.* 2014. *J Immunol.* 192:5426. [PubMed](#)
103. Sreekumar PG, *et al.* 2018. *J Control Release.* 283:94. [PubMed](#)
104. Garo LP, *et al.* 2019. *Cell Rep.* 28:3353. [PubMed](#)
105. Li W, *et al.* 2019. *Nat Commun.* 10:3349. [PubMed](#)
106. Xu X, *et al.* 2018. *Cell.* 175:1336. [PubMed](#)
107. Reismann D, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-01538-9. [PubMed](#)
108. Ishidome T *et al.* 2017. *EBioMedicine.* 22:89-99. [PubMed](#)
109. Ding Y, *et al.* 2022. *Cell Death Dis.* 13:996. [PubMed](#)
110. Tang X, *et al.* 2022. *Cell Rep.* 41:111673. [PubMed](#)
111. Wei W, *et al.* 2022. *mSystems.* 7:e0046922. [PubMed](#)
112. Zhao X, *et al.* 2022. *Nat Protoc.* 17:2240. [PubMed](#)
113. Zhou H, *et al.* 2022. *Oncoimmunology.* 11:2057892. [PubMed](#)
114. Yang J, *et al.* 2022. *Microbiome.* 10:149. [PubMed](#)
115. Harnett MM, *et al.* 2022. *Front Immunol.* 13:953053. [PubMed](#)
116. Koren E, *et al.* 2022. *Nat Commun.* 13:4628. [PubMed](#)
117. Chen X, *et al.* 2021. *Cell Rep.* 37:109991. [PubMed](#)
118. Ye P, *et al.* 2022. *Front Cardiovasc Med.* 8:810477. [PubMed](#)
119. Zuo S, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
120. Reinfield BI, *et al.* 2021. *Nature.* 593:282. [PubMed](#)
121. Du J, *et al.* 2012. *Stem Cells.* 30:1447. [PubMed](#)
122. Weinheimer-Haus E, *et al.* 2014. *PLoS One.* 9:91355. [PubMed](#)
123. Zheng L, *et al.* 2020. *Front Oncol.* 10:531131. [PubMed](#)
124. Kruta M, *et al.* 2021. *Cell Stem Cell.* [PubMed](#)
125. Moon HG *et al.* 2018. *Immunity.* 49(2):275-287. [PubMed](#)
126. Ren W, *et al.* 2018. *Mucosal Immunol.* 12:531. [PubMed](#)
127. Liu W, *et al.* 2021. *Cell Death Discov.* 7:136. [PubMed](#)
128. França TT, *et al.* 2021. *JCI Insight.* 6: [PubMed](#)
129. Carbone C, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
130. Shannon JP, *et al.* 2021. *STAR Protoc.* 2:100790. [PubMed](#)
131. Sun C, *et al.* 2022. *J Adv Res.* 35:71. [PubMed](#)
132. Alsina-Sanchis E, *et al.* 2020. *Mol Cancer Res.* [PubMed](#)
133. Shannon JP, *et al.* 2021. *Immunity.* 54(2):276-290.e5. [PubMed](#)
134. Choi EW, *et al.* 2020. *Sci Rep.* 10:12001. [PubMed](#)
135. Yu X, *et al.* 2019. *Nat Commun.* 10:574. [PubMed](#)
136. Cohen M *et al.* 2018. *Cell.* 175(4):1031-1044. [PubMed](#)
137. Ma W, *et al.* 2017. *Cell Death & Disease.* 10.1038/cddis.2017.47. [PubMed](#)
138. Yang Z, *et al.* 2021. *Onco Targets Ther.* 14:4239. [PubMed](#)
139. Puigdelloses M, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
140. Frost JN, *et al.* 2021. *Med (N Y).* 2:164. [PubMed](#)
141. Port JR, *et al.* 2020. *J Virol.* 94: [PubMed](#)
142. Rashid MH, *et al.* 2021. *Oncol Rep.* 45:1171. [PubMed](#)
143. Li Y, *et al.* 2021. *Cell Death Dis.* 12:1001. [PubMed](#)
144. Zhang W, *et al.* 2019. *Mar Drugs.* 0.845138889. [PubMed](#)
145. Nowlan B, *et al.* 2019. *Haematologica.* 105:71. [PubMed](#)
146. Zhang W, *et al.* 2020. *Nat Commun.* 11:1187. [PubMed](#)
147. Yu H, *et al.* 2021. *Front Oncol.* 11:736882. [PubMed](#)
148. Xiao Y, *et al.* 2022. *Nat Commun.* 13:758. [PubMed](#)
149. Zhang R, *et al.* 2022. *Front Pharmacol.* 13:870848. [PubMed](#)
150. Ali S, *et al.* 2021. *PLoS One.* 16:e0246646. [PubMed](#)
151. Yang Z, *et al.* 2021. *Nat Commun.* 12:4852. [PubMed](#)
152. Wang Z, *et al.* 2021. *Acta Pharm Sin B.* 694:11. [PubMed](#)
153. Chen R, *et al.* 2021. *Cell Reports.* 34(7):108751. [PubMed](#)
154. Wu L, *et al.* 2020. *Cell Rep.* 33:108327. [PubMed](#)
155. Zan H, *et al.* 2017. *Nat Commun.* 8:14244. [PubMed](#)
156. Cabrera-Perez J, *et al.* 2016. *J Immunol.* 197: 1692 - 1698. [PubMed](#)
157. Kang J, Lee J, Chang J 2016. *PLoS One.* 11: 0157015. [PubMed](#)
158. Cabrera-Perez C, *et al.* 2015. *J Immunol.* 194:1609-20. [PubMed](#)
159. He J, *et al.* 2020. *Evid Based Complement Alternat Med.* 2020:5637507. [PubMed](#)
160. Roy S, *et al.* 2019. *Front Immunol.* 2.404166667. [PubMed](#)
161. Scally S, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-01924-3. [PubMed](#)
162. Yi H, *et al.* 2021. *Front Immunol.* 12:719189. [PubMed](#)
163. Qi J, *et al.* 2021. *Nat Commun.* 12:4755. [PubMed](#)
164. Bent EH, *et al.* 2021. *Nat Commun.* 12:6218. [PubMed](#)
165. Zhang YN, *et al.* 2021. *Sci Adv.* 7:eabj3107. [PubMed](#)
166. Murdock BJ, *et al.* 2021. *JCI Insight.* 6: [PubMed](#)
167. Robertson TF, *et al.* 2021. *J Cell Biol.* 220: [PubMed](#)
168. Mohammadi MR, *et al.* 2021. *Commun Biol.* 4:685. [PubMed](#)
169. Li X, *et al.* 2021. *Cell Death Dis.* 12:314. [PubMed](#)
170. Chen X, *et al.* 2019. *Med Sci Monit.* 25:5389. [PubMed](#)
171. Zhang X, *et al.* 2021. *Nat Commun.* 12:4536. [PubMed](#)
172. Smith-Diaz CC, *et al.* 2021. *Front Oncol.* 11:709543. [PubMed](#)

173. Tsai HI, *et al.* 2021. *EMBO Mol Med.* 13:e12834. [PubMed](#)
174. Wang J, *et al.* 2022. *Clin Transl Med.* 12:e718. [PubMed](#)
175. Lai Y, *et al.* 2022. *Clin Transl Med.* 12:e999. [PubMed](#)
176. Zhang J, *et al.* 2022. *Biomater Res.* 26:44. [PubMed](#)
177. Li M, *et al.* 2021. *Br J Pharmacol.* 178:2617. [PubMed](#)
178. Yang YS, *et al.* 2022. *Nat Commun.* 13:6175. [PubMed](#)
179. Harb H, *et al.* 2020. *Nat Immunol.* 1359:21. [PubMed](#)
180. Campolo M, *et al.* 2020. *Int J Mol Sci.* 21:00. [PubMed](#)
181. Baumann D, *et al.* 2020. *Nat Commun.* 1.969444444. [PubMed](#)
182. Chen C, *et al.* 2020. *Front Cell Neurosci.* 14:8. [PubMed](#)
183. Clemente-Casares X, *et al.* 2017. *Immunity.* 47:974. [PubMed](#)
184. Chen Y, *et al.* 2022. *Nat Commun.* 13:4468. [PubMed](#)
185. Nam J, *et al.* 2021. *Adv Ther (Weinh).* 4:. [PubMed](#)
186. Leary N, *et al.* 2022. *J Extracell Vesicles.* 11:e12197. [PubMed](#)
187. Zhou H, *et al.* 2021. *Cell Death Discov.* 7:332. [PubMed](#)
188. Yang Z, *et al.* 2021. *Nat Commun.* 12:4299. [PubMed](#)
189. van den Berk P, *et al.* 2020. *Cell Rep.* 33:108533. [PubMed](#)
190. Xu Y, *et al.* 2016. *Nat Commun.* 7:12073. [PubMed](#)
191. Zheng DW, *et al.* 2020. *Nat Commun.* 3.865972222. [PubMed](#)
192. Jia H, *et al.* 2018. *Int J Oncol.* 53:949. [PubMed](#)
193. Chao Y, *et al.* 2020. *Sci Adv.* 6:eaa4204. [PubMed](#)
194. Jiang Y, *et al.* 2021. *Nat Commun.* 12:742. [PubMed](#)
195. Magee JA, *et al.* 2021. *Stem Cell Reports.* 16:20. [PubMed](#)
196. Fujimoto M, *et al.* 2022. *Nat Commun.* 13:5408. [PubMed](#)
197. Cané S, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
198. Ravindran Menon D, *et al.* 2021. *Pharmaceuticals (Basel).* 14:. [PubMed](#)
199. Le QV, *et al.* 2022. *Bioact Mater.* 15:160. [PubMed](#)
200. Aulova KS, *et al.* 2022. *Molecules.* 27:. [PubMed](#)
201. Yang N, *et al.* 2022. *Nat Commun.* 13:2336. [PubMed](#)
202. Guo X, *et al.* 2020. *J Cell Mol Med.* . [PubMed](#)
203. Simoni L, *et al.* 2020. *Cell Rep.* 33:108330. [PubMed](#)
204. Yu H, *et al.* 2015. *PLoS One.* 10: 0143001. [PubMed](#)
205. Pan X, *et al.* 2019. *BMC Complement Altern Med.* 19:163. [PubMed](#)
206. Li K, *et al.* 2020. *Nat Commun.* 0.795138889. [PubMed](#)
207. Hidalgo San Jose L, *et al.* 2020. *Cell Rep.* 30:69. [PubMed](#)
208. Zukauskas A, *et al.* 2018. *mSphere.* 3:e00303. [PubMed](#)
209. Tao Z, *et al.* 2022. *Cells.* 11:. [PubMed](#)
210. Tang T, *et al.* 2022. *J Immunother Cancer.* 10:. [PubMed](#)
211. Zhou Y, *et al.* 2022. *Theranostics.* 12:5488. [PubMed](#)
212. Chen LH, *et al.* 2021. *Sci Rep.* 11:19478. [PubMed](#)
213. Liu X, *et al.* 2021. *Adv Sci (Weinh).* 8:e2100233. [PubMed](#)
214. Wang J, *et al.* 2021. *Am J Cancer Res.* 11:2005. [PubMed](#)
215. Wang F, *et al.* 2021. *Neoplasia.* 23:281. [PubMed](#)
216. Roberto MP, *et al.* 2021. *Immunity.* 54(8):1807-1824.e14. [PubMed](#)
217. Goldberg EL, *et al.* 2021. *Cell Metabolism.* .: [PubMed](#)
218. Tanegashima K *et al.* 2017. *EBioMedicine.* 24:247-256 . [PubMed](#)
219. Crowe J, *et al.* 2020. *PLoS Pathog.* 16:e1008391. [PubMed](#)
220. Tur J, *et al.* 2020. *Cell Reports.* 32(8):108079. [PubMed](#)
221. Mincham KT, *et al.* 2021. *Front Immunol.* 11:601494. [PubMed](#)
222. Zheng Y, *et al.* 2022. *Transl Res.* .: [PubMed](#)
223. Gawish R, *et al.* 2022. *Elife.* 11:. [PubMed](#)
224. Li J, *et al.* 2022. *Nat Commun.* 13:1481. [PubMed](#)
225. Li J, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
226. Trivedi S, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
227. Tripathi D, *et al.* 2016. *Nat Commun.* 7:13896. [PubMed](#)
228. Fan X, *et al.* 2014. *PLoS One.* 9:107638. [PubMed](#)
229. Martínez-Vicente P, *et al.* 2019. *PLoS Pathog.* 15:e1007658. [PubMed](#)
230. Liu WL, *et al.* 2019. *Nat Commun.* 10:3199. [PubMed](#)
231. Kubli SP, *et al.* 2019. *Nat Commun.* 10:2678. [PubMed](#)
232. Sun Q, *et al.* 2022. *J Inflamm Res.* 15:5827. [PubMed](#)
233. Cao Y, *et al.* 2022. *Small.* 18:e2203466. [PubMed](#)
234. Li C, *et al.* 2022. *Front Cell Dev Biol.* 10:913824. [PubMed](#)
235. Xu Z, *et al.* 2022. *Cell Death Dis.* 13:502. [PubMed](#)
236. Erens C, *et al.* 2022. *Biomedicines.* 10:. [PubMed](#)
237. Zhang J, *et al.* 2021. *Stem Cell Res Ther.* 12:579. [PubMed](#)
238. Gu Z, *et al.* 2021. *Nat Genet.* 53:672. [PubMed](#)
239. Zuo S, *et al.* 2021. *EBioMedicine.* 64:103240. [PubMed](#)
240. Zheng QY, *et al.* 2020. *FASEB J.* 34:10590. [PubMed](#)

RRID

AB_312660 (BioLegend Cat. No. 100203)
 AB_312661 (BioLegend Cat. No. 100204)

Antigen Details

Structure

Ig superfamily, CD3/TCR, 20 kD

Distribution	Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function	Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor	Peptide antigen/MHC-complex
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475. 3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.
Gene ID	12502


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

FITC anti-mouse CD3, PE anti-mouse CD3, Purified anti-mouse CD3, Alexa Fluor® 647 anti-mouse CD3, Alexa Fluor® 488 anti-mouse CD3, Pacific Blue™ anti-mouse CD3, Alexa Fluor® 700 anti-mouse CD3, PerCP/Cyanine5.5 anti-mouse CD3, PE/Cyanine7 anti-mouse CD3, APC/Cyanine7 anti-mouse CD3, Brilliant Violet 421™ anti-mouse CD3, Brilliant Violet 570™ anti-mouse CD3, Brilliant Violet 650™ anti-mouse CD3, Brilliant Violet 785™ anti-mouse CD3, Brilliant Violet 510™ anti-mouse CD3, APC anti-mouse CD3, Ultra-LEAF™ Purified anti-mouse CD3, Brilliant Violet 605™ anti-mouse CD3, Alexa Fluor® 594 anti-mouse CD3, Brilliant Violet 711™ anti-mouse CD3, Biotin anti-mouse CD3, PE/Dazzle™ 594 anti-mouse CD3, APC/Fire™ 750 anti-mouse CD3, Brilliant Violet 750™ anti-mouse CD3, TotalSeq™-A0182 anti-mouse CD3, TotalSeq™-B0182 anti-mouse CD3, Spark Blue™ 550 anti-mouse CD3, Spark NIR™ 685 anti-mouse CD3, TotalSeq™-C0182 anti-mouse CD3, APC/Fire™ 810 anti-mouse CD3, PE/Fire™ 640 anti-mouse CD3, Spark YG™ 570 anti-mouse CD3, PE/Fire™ 700 anti-mouse CD3, PE/Cyanine5 anti-mouse CD3, Spark Blue™ 574 anti-mouse CD3 Antibody, Spark Violet™ 423 anti-mouse CD3, PE/Fire™ 810 anti-mouse CD3, Spark Red™ 718 anti-mouse CD3

Product Data



C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587